Published in Dis Markers on November 18, 2013
Cancer statistics, 2013. CA Cancer J Clin (2013) 84.72
Oncogenic kinase signalling. Nature (2001) 16.30
Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology (2008) 15.86
Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet (2010) 15.50
Autoantibody signatures in prostate cancer. N Engl J Med (2005) 7.56
Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature (2000) 7.10
A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A (1997) 6.67
Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat Biotechnol (2002) 3.32
p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res (2000) 3.31
Next-generation high-density self-assembling functional protein arrays. Nat Methods (2008) 2.46
Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. Adv Exp Med Biol (2001) 2.42
Proteomics-based identification of RS/DJ-1 as a novel circulating tumor antigen in breast cancer. Clin Cancer Res (2001) 2.28
The sentinel within: exploiting the immune system for cancer biomarkers. J Proteome Res (2005) 2.22
Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays. Cancer Res (2006) 2.08
Cancer screening in the United States, 2012: A review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin (2012) 2.00
Serum autoantibodies as biomarkers for early cancer detection. FEBS J (2009) 1.94
An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc Natl Acad Sci U S A (2001) 1.85
Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis. J Clin Invest (2001) 1.81
Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes. Cancer Res (2010) 1.79
Tumor-associated carbohydrate antigens. Annu Rev Immunol (1984) 1.76
Application of protein microarrays for multiplexed detection of antibodies to tumor antigens in breast cancer. J Proteome Res (2008) 1.63
Clinical validation of an autoantibody test for lung cancer. Ann Oncol (2010) 1.55
Cancer immunomics using autoantibody signatures for biomarker discovery. Mol Cell Proteomics (2007) 1.47
CA 15-3: uses and limitation as a biomarker for breast cancer. Clin Chim Acta (2010) 1.43
Interactions between galectin-3 and Mac-2-binding protein mediate cell-cell adhesion. Cancer Res (1996) 1.41
Immune response as a biomarker for cancer detection and a lot more. N Engl J Med (2005) 1.35
90K (Mac-2 BP) and galectins in tumor progression and metastasis. Glycoconj J (2004) 1.33
Tumor-associated antigen arrays for the serological diagnosis of cancer. Mol Cell Proteomics (2006) 1.32
Autoantibodies in breast cancer sera: candidate biomarkers and reporters of tumorigenesis. Cancer Lett (2005) 1.26
Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancer patients. Cancer Res (2002) 1.16
Philip Levine award lecture. Blood group antigens as markers for normal differentiation and malignant change in human tissues. Am J Clin Pathol (1987) 1.12
Tumor-associated antigen 90K/Mac-2-binding protein: possible role in colon cancer. J Cell Biochem (2006) 1.09
Prognostic value of a novel circulating serum 90K antigen in breast cancer. Br J Cancer (1994) 1.08
Molecular profiling of the immune response in colon cancer using protein microarrays: occurrence of autoantibodies to ubiquitin C-terminal hydrolase L3. Proteomics (2003) 1.06
Multiple hepatic receptors cooperate to eliminate secretory mucins aberrantly entering the bloodstream: are circulating cancer mucins the "tip of the iceberg"? Cancer Res (2006) 1.04
The functioning antigens: beyond just as the immunological targets. Cancer Sci (2009) 1.01
Identification of 14-3-3 theta as an antigen that induces a humoral response in lung cancer. Cancer Res (2007) 1.00
Comparison of candidate serologic markers for type I and type II ovarian cancer. Gynecol Oncol (2011) 0.97
Measurement of a breast cancer associated antigen detected by monoclonal antibody SP-2 in sera of cancer patients. Breast Cancer Res Treat (1988) 0.95
Detection of cancer before distant metastasis. BMC Cancer (2013) 0.94
The footprints of cancer development: Cancer biomarkers. Cancer Treat Rev (2008) 0.93
Circulating immunostimulatory protein 90K and soluble interleukin-2-receptor in human ovarian cancer. Int J Cancer (1996) 0.91
High expression of 90K (Mac-2 BP) is associated with poor survival in node-negative breast cancer patients not receiving adjuvant systemic therapies. Int J Cancer (2009) 0.82
An Antibody-based Blood Test Utilizing a Panel of Biomarkers as a New Method for Improved Breast Cancer Diagnosis. Biomark Cancer (2013) 0.76